We describe a drug-based, genetic platform consisting of four selection and two counterselection markers eliminating the need to screen for transgenic progeny. These markers work reliably individually, or in combination, to produce specific genetic outcomes.We perform immunoprecipitation followed by proteomic analysis on one tagged BAC line demonstrating our platform’s applicability to biological discovery.